NIAID's Carl Dieffenbach, Ph.D., joins Anne Rancourt to discuss some key takeaways from the 10th International AIDS Society Conference on HIV Science.
Last fall, community activists voiced concerns over the roll out of studies on Descovy (TAF/FTC) as pre-exposure prophylaxis (PrEP) without adequately involving community advisors.
Long-acting injectable treatment takes another step closer to being a real-world option for people living with HIV, with new study results presented at IAS 2017.
The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the U.S. Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become ava...
Ibalizumab, a drug that works against multi-drug-resistant HIV, is now available via the manufacturer's expanded access program.
You may have heard about the "HIV cure with gene editing in animals" story. Here's some help making sense of the story, including what's true or not, and what to get excited about.
In a way, the story of ibalizumab is a time travel tale back to 1994, before any protease inhibitor drugs were approved.
For the small percentage of HIV patients struggling with drug resistance, an expanded access program for a new injectable treatment might be the answer.
HIV Activists Seek to Accelerate Development of Immune Enhancing Therapies for Immunologic Non-Responders
A coalition of HIV/AIDS activists are calling for renewed attention to HIV-positive people termed immunologic non-responders.
"Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial," write Anna Forbes and Marc-André LeBlanc, explaining that concern is inspired, in part, by controversies in earlier PrEP trials...